Clera home
·Dashboard

Jobs at Immuneering Corporation (Now Hiring) — 2 open

Immuneering Corporation logoImmuneering Corporation

Senior Medical Science Liaison

Sandwell, England, United Kingdom · Remote OK

$220k–$270k/yr

Mid level$337M raised

ABOUT IMMUNEERING Immuneering Corporation (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company developing oncology therapies using its proprietary Deep Cyclic Inhibition platform. Our lead asset, atebimetinib (IM…

Skills: KOL Relationship Management, Oncology Clinical Trial Design, Scientific Exchange, Medical Affairs Strategy, RAS/MAPK Pathway Biology

Immuneering Corporation logoImmuneering Corporation

Director, Pharmacovigilance

Remote Solely

$280k–$350k/yr

Senior$337M raised

ABOUT IMMUNEERING Immuneering Corporation (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company developing oncology therapies using its proprietary Deep Cyclic Inhibition platform. Our lead asset, atebimetinib (IM…

Skills: Pharmacovigilance, Safety Surveillance, Signal Detection, Risk Management, ICSR Management

Immuneering Corporation logo

Senior Medical Science Liaison

Immuneering Corporation

Sandwell, England, United Kingdom • Remote OK

Apply
Mid level

Tired of cold applications?

Sign up with Clera and we'll reach out the moment a role actually fits you — no more spraying applications into the void.

  • $220k–$270k/yr
  • Full-time
  • postgraduate degree
  • Posted 14d ago
  • ~40 hrs/week
  • Remote in 4S Ranch, California, United States, Cambridge, Massachusetts, United States, New York, New York, United States

Responsibilities

Establish the company's scientific presence by managing relationships with oncology KOLs and supporting Phase 3 clinical trial enrollment. Deliver compliant scientific exchange on Deep Cyclic Inhibition and provide field insights to internal stakeholders.

Requirements

Requires an advanced health science degree (MD, PharmD, PhD, or MSN/NP/PA) and 3-5+ years of oncology MSL experience. Must have established KOL relationships in pancreatic or thoracic oncology and the ability to travel 50-60% domestically.

Full job description

ABOUT IMMUNEERING

Immuneering Corporation (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company developing oncology therapies using its proprietary Deep Cyclic Inhibition platform. Our lead asset, atebimetinib (IMM-1-104), is an oral, once-daily Deep Cyclic Inhibitor of MEK in active Phase 2 and Phase 3 (MAPKeeper 301) clinical trials in pancreatic cancer and RAS-mutant non-small cell lung cancer, as well as additional solid tumor programs. We are committed to delivering transformative treatments to patients with limited options through rigorous science and a collaborative, mission-driven culture.

POSITION SUMMARY 

This is a foundational hire. As Immuneering’s first US-based field medical employee, this role will establish the company’s scientific presence with key opinion leaders and academic oncology centers nationwide. This role is best suited for a senior MSL who is willing to engage with KOLs enthusiastically and build a rapport with the scientific community, with the strategic vision and potential to grow into a leadership position within a lean, mission-driven organization. The selected MSL may have the opportunity to assist with the company’s international MSL buildout across Western Europe, Central-Eastern Europe, and the Australia/APAC region, and could quickly step into the role of Field Medical Director. 

US Field Medical Affairs 

  • Develop and manage peer-to-peer scientific relationships with oncology KOLs, academic investigators, and institutional stakeholders at priority centers including MSKCC, City of Hope, OHSU, and the SCRI/USON/OneOncology networks and others. 
  • As a major priority, this individual will support investigator identification and engagement for MAPKeeper 301 Phase 3 enrollment; facilitate site activation and scientific readiness at high-enrolling centers. 
  • Deliver accurate, balanced, and compliant scientific exchange on Immuneering’s Deep Cyclic Inhibition mechanism, MAPKeeper in metastatic pancreatic cancer, atebimetinib + cemiplimab in RAS-mutant NSCLC and other possible studies related to the MAPK pathway. 
  • Respond to unsolicited medical information requests from healthcare professionals in accordance with FDA guidelines on scientific exchange. 
  • Generate and communicate field insights — including HCP perspectives, competitive intelligence, and clinical practice patterns — to Medical Affairs, Clinical, and Commercial stakeholders. 
  • Provide flexible US territory coverage (East, Central/South, West) based on enrollment priorities and KOL geography. 
  • Represent Immuneering at national and regional oncology congresses (possibly including ASCO, AACR, ESMO and others). 

Global MSL Network Leadership 

  • Partner with Medical Affairs leadership to develop scientific messaging frameworks, training curricula, and field activity standards for the global consultant network. 
  • May quickly transform into a leadership position as the Field Medical Director, which would entail managing the buildout of Immuneering’s OUS consultant MSL network across the UK/Western Europe, Central-Eastern Europe (Poland, Czech Republic, Hungary, Romania), and Australia/APAC. 
  • Contribute to MSL infrastructure, SOPs, and reporting frameworks as Immuneering scales toward commercialization or partnership.

Education 

  • Advanced degree in a health science discipline (MD, PharmD, PhD, or MSN/NP/PA with oncology specialization) 
  • 3–5+ years of MSL experience in oncology; prior experience at a biotech or clinical-stage company strongly preferred

Technical / Soft Skills 

Required 

  • Established KOL relationships in pancreatic cancer, thoracic oncology, or a closely adjacent tumor type 
  • Deep understanding of clinical trial design, oncology drug development, and FDA-compliant scientific exchange 
  • Ability to translate complex mechanistic science (RAS/MAPK pathway biology, adaptive resistance, combination strategies) for diverse oncology audiences 
  • Willingness and ability to travel 50–60% domestically; occasional international travel for global team alignment and congresses 
  • US-based; eligible to work in the United States without sponsorship 

Preferred 

  • Background in RAS/MEK pathway biology, GI oncology, or thoracic oncology 
  • Experience supporting Phase 2 or Phase 3 clinical trial enrollment as an MSL 
  • Prior experience in a lead MSL, field medical director, or senior leadership field medical role 
  • Familiarity with medical affairs operations in an international or multi-regional context 
  • Experience working with or coordinating medical affairs consultants or CRO-based MSL models

EQUAL OPPORTUNITY EMPLOYER

Immuneering Corporation is an equal opportunity employer. We celebrate diversity and are committed to creating an inclusive environment for all employees. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, national origin, disability, protected veteran status, or any other characteristic protected by law.

Related keywords

Medical Science LiaisonOncologyBiopharmaceuticalDeep Cyclic InhibitionMEK InhibitorPancreatic CancerNSCLCRAS-mutantMAPK PathwayKOLPhase 2Phase 3Clinical TrialsMedical AffairsFDA GuidelinesASCO

About Immuneering Corporation

LinkedInVisit site

Better Medicines Through Signaling Dynamics

Industry
Biotechnology
Company size
11-50 employees
Founded
2008
Headquarters
Cambridge, MA
LinkedIn followers
4,111
Total funding
$337M

Immuneering is a biopharmaceutical company with an emerging pipeline focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying its deep knowledge of translational bioinformatics to every stage of the drug development process. Immuneering has more than a decade of experience in translational bioinformatics and generating insights into drug mechanisms of action and patient treatment responses. Building on this experience, Immuneering has developed a disease-agnostic platform that enables the company to utilize human data, novel biology and chemistry, and translational planning to create and advance its wholly owned pipeline. Immuneering’s current development programs in oncology are focused on providing potential treatments for patients with solid tumors caused by mutations of oncologic signaling pathways, including the MAPK pathway. Immuneering’s lead product candidate, IMM-1-104, is designed to be a highly selective dual-MEK inhibitor that further disrupts KSR for the treatment of advanced solid tumors in patients harboring RAS mutant tumors. Additionally, Immuneering has six other oncology programs in the discovery stage that are designed to target either the MAPK or mTOR pathway, and two neuroscience programs in the discovery stage. For more information, please visit www.immuneering.com.

Offices: 245 Main Street, Second Floor, Cambridge, MA 02142, US · 667 Madison Avenue, 5th Floor, New York, NY 10065, US · 9620 Towne Centre Dr, #100, San Diego, CA 92121, US

Computational BiologyGenomicsDrug DevelopementNeurodegenerative Diseaseand OncologyBiotechnologyMedicalPharmaceutical
View all jobs at Immuneering Corporation

About Immuneering Corporation

LinkedInVisit site

Better Medicines Through Signaling Dynamics

Industry
Biotechnology
Company size
11-50 employees
Founded
2008
Headquarters
Cambridge, MA
LinkedIn followers
4,111
Total funding
$337M

Immuneering is a biopharmaceutical company with an emerging pipeline focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying its deep knowledge of translational bioinformatics to every stage of the drug development process. Immuneering has more than a decade of experience in translational bioinformatics and generating insights into drug mechanisms of action and patient treatment responses. Building on this experience, Immuneering has developed a disease-agnostic platform that enables the company to utilize human data, novel biology and chemistry, and translational planning to create and advance its wholly owned pipeline. Immuneering’s current development programs in oncology are focused on providing potential treatments for patients with solid tumors caused by mutations of oncologic signaling pathways, including the MAPK pathway. Immuneering’s lead product candidate, IMM-1-104, is designed to be a highly selective dual-MEK inhibitor that further disrupts KSR for the treatment of advanced solid tumors in patients harboring RAS mutant tumors. Additionally, Immuneering has six other oncology programs in the discovery stage that are designed to target either the MAPK or mTOR pathway, and two neuroscience programs in the discovery stage. For more information, please visit www.immuneering.com.

Offices: 245 Main Street, Second Floor, Cambridge, MA 02142, US · 667 Madison Avenue, 5th Floor, New York, NY 10065, US · 9620 Towne Centre Dr, #100, San Diego, CA 92121, US

Computational BiologyGenomicsDrug DevelopementNeurodegenerative Diseaseand OncologyBiotechnologyMedicalPharmaceutical
View all jobs at Immuneering Corporation

Similar companies hiring

Regeneron (357)Prism.bio (209)Acrotech Biopharma Inc (66)Travere Therapeutics (47)Hamilton Company (46)Beeflow (24)Xencor (17)CARSO (17)BioBridge Global (13)ProFarm (12)Avalo Therapeutics (11)Krystal Biotech, Inc. (11)
Clera home

Your AI-talent agent. Connecting talents with dream jobs.

Earn $5,000

Tools

  • Salary Calculator
  • Resume Review
  • Startup Map

Explore

  • Jobs
  • Discover Jobs
  • Companies
  • Referral

Platform

  • Pricing
  • Integrations
  • Partners
  • Acquihire

Clera

  • Manifesto
  • Engineering
  • We are hiring!
  • FAQs
  • Blog
  • Press

Tools

  • Salary Calculator
  • Resume Review
  • Startup Map

Explore

  • Jobs
  • Discover Jobs
  • Companies
  • Referral

Platform

  • Pricing
  • Integrations
  • Partners
  • Acquihire

Clera

  • Manifesto
  • Engineering
  • We are hiring!
  • FAQs
  • Blog
  • Press

© 2026 Clera Labs, Inc.

PrivacyTermsBug Bounty